Vancomycin
Firvanq, Vancocin (vancomycin) is a small molecule pharmaceutical. Vancomycin was first approved as Vancocin hydrochloride on 1982-01-01. It is used to treat bacterial endocarditis, bacterial infections, diarrhea, neutropenia, and pneumococcal meningitis amongst others in the USA.
Download report
Favorite
Searched
Commercial
Trade Name
FDA
EMA
Firvanq, Vancocin (generic drugs available since 1983-07-13, discontinued: Vancoled, Vancor)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Vancomycin
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
VANCOMYCIN | Xellia | N-213895 RX | 2021-08-26 | 1 products, RLD, RS |
Vancomycin hydrochloride
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
VANCOCIN HYDROCHLORIDE | ANI PHARMS | N-050606 RX | 1986-04-15 | 2 products, RLD, RS |
FIRVANQ KIT | Azurity | N-208910 RX | 2018-01-26 | 2 products, RLD, RS |
VANCOCIN HYDROCHLORIDE IN PLASTIC CONTAINER | Baxter | N-050671 RX | 1993-04-29 | 3 products, RLD, RS |
VANCOMYCIN HYDROCHLORIDE | Mylan | N-209481 RX | 2018-07-10 | 3 products, RLD, RS |
VANCOMYCIN HYDROCHLORIDE | Xellia | N-211962 RX | 2019-02-15 | 7 products, RLD, RS |
VANCOMYCIN HYDROCHLORIDE | Zhejiang Novus Pharmaceuticals | N-210274 RX | 2023-01-20 | 4 products, RLD, RS |
Show 1 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
---|---|---|
firvanq | New Drug Application | 2021-12-17 |
vancocin | New Drug Application | 2022-01-04 |
vancomycin hydrochloride | ANDA | 2023-05-19 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
bacterial endocarditis | EFO_1000830 | D004697 | — |
bacterial infections | — | D001424 | A49 |
diarrhea | HP_0002014 | D003967 | R19.7 |
neutropenia | — | D009503 | D70 |
pneumococcal meningitis | EFO_1001114 | D008586 | G00.1 |
postoperative complications | — | D011183 | — |
pseudomembranous enterocolitis | EFO_1001314 | D004761 | A04.7 |
staphylococcal infections | — | D013203 | A49.01 |
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent | Expires | Flag | FDA Information |
---|---|---|---|
Vancomycin, Vancomycin, Xellia Pharms Aps | |||
10039804 | 2035-11-06 | DP | U-282 |
10188697 | 2035-11-06 | DP | U-282 |
10849956 | 2035-11-06 | DP | |
11000567 | 2035-11-06 | DP | |
11517609 | 2035-11-06 | U-282 | |
Vancomycin Hydrochloride, Vancomycin Hydrochloride, Xellia Pharms Aps | |||
11628200 | 2035-11-06 | DP | |
Vancomycin Hydrochloride, Firvanq Kit, Azurity | |||
10493028 | 2035-03-13 | DP | |
10688046 | 2035-03-13 | DP | |
10959946 | 2035-03-13 | DP | |
10959947 | 2035-03-13 | DP | U-3104, U-3105 |
10959948 | 2035-03-13 | DP | U-3104, U-3105 |
10959949 | 2035-03-13 | DP | U-3104, U-3105 |
11638692 | 2035-03-13 | DP |
ATC Codes
A: Alimentary tract and metabolism drugs
— A07: Antidiarrheals, intestinal antiinflammatory/antiinfective agents
— A07A: Intestinal antiinfectives
— A07AA: Antibiotics, intestinal
— A07AA09: Vancomycin
J: Antiinfectives for systemic use
— J01: Antibacterials for systemic use
— J01X: Other antibacterials in atc
— J01XA: Glycopeptide antibacterials
— J01XA01: Vancomycin
S: Sensory organ drugs
— S01: Ophthalmologicals
— S01A: Antiinfective ophthalmologics
— S01AA: Antibiotics, ophthalmologic
— S01AA28: Vancomycin
HCPCS
Code | Description |
---|---|
J3370 | Injection, vancomycin hcl, 500 mg |
Clinical
Clinical Trials
356 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Clostridium infections | D003015 | EFO_1000874 | A05.2 | 4 | 11 | 19 | 10 | 4 | 44 |
Infections | D007239 | EFO_0000544 | 2 | 4 | 7 | 8 | 11 | 30 | |
Surgical wound infection | D013530 | 1 | 3 | 5 | 9 | 6 | 22 | ||
Bacteremia | D016470 | EFO_0003033 | R78.81 | — | 5 | 4 | 7 | 2 | 17 |
Methicillin-resistant staphylococcus aureus | D055624 | 2 | 1 | 2 | 5 | 2 | 12 | ||
Clostridioides difficile | D016360 | NCBITaxon_1496 | — | 4 | 4 | 4 | 1 | 12 | |
Sepsis | D018805 | A41.9 | 1 | — | 2 | 2 | 6 | 11 | |
Soft tissue infections | D018461 | — | 1 | 6 | 1 | 1 | 9 | ||
Endocarditis | D004696 | EFO_0000465 | I33 | — | 1 | 2 | 4 | 2 | 9 |
Wound infection | D014946 | — | 2 | 4 | 3 | — | 9 |
Show 41 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Bacterial infections | D001424 | A49 | 1 | 5 | 5 | — | 1 | 12 | |
Cystic fibrosis | D003550 | EFO_0000390 | E84 | 2 | 2 | 1 | — | — | 5 |
Abscess | D000038 | EFO_0003030 | — | 1 | 4 | — | — | 5 | |
Neoplasms | D009369 | C80 | 1 | 2 | 1 | — | 1 | 4 | |
Inflammation | D007249 | 1 | — | 2 | — | — | 3 | ||
Bacterial pneumonia | D018410 | EFO_1001272 | J15.9 | — | 1 | 2 | — | — | 3 |
Skin diseases | D012871 | L00-L99 | — | — | 2 | — | — | 2 | |
Neutropenia | D009503 | D70 | — | — | 1 | — | 1 | 2 | |
Bacterial skin diseases | D017192 | — | — | 2 | — | — | 2 | ||
Cross infection | D003428 | — | — | 1 | — | — | 1 |
Show 20 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Ulcerative colitis | D003093 | EFO_0000729 | K51 | 2 | 2 | — | — | 1 | 5 |
Autism spectrum disorder | D000067877 | F84.0 | 2 | 3 | — | — | 1 | 5 | |
Obesity | D009765 | EFO_0001073 | E66.9 | 1 | 1 | — | — | 2 | 4 |
Colorectal neoplasms | D015179 | 1 | 3 | — | — | — | 3 | ||
Respiratory tract infections | D012141 | J06.9 | 1 | 1 | — | — | 1 | 3 | |
Healthcare-associated pneumonia | D000077299 | — | 1 | — | — | 2 | 3 | ||
Melanoma | D008545 | 2 | 1 | — | — | — | 2 | ||
Liver neoplasms | D008113 | EFO_1001513 | C22.0 | — | 2 | — | — | — | 2 |
Neonatal sepsis | D000071074 | HP_0040187 | — | 1 | — | — | 1 | 2 | |
Crohn disease | D003424 | EFO_0000384 | K50 | — | 2 | — | — | — | 2 |
Show 17 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Critical illness | D016638 | 1 | — | — | — | 3 | 4 | ||
Inflammatory bowel diseases | D015212 | EFO_0003767 | 1 | — | — | — | 2 | 3 | |
Healthy volunteers/patients | — | 2 | — | — | — | 1 | 3 | ||
Biliary atresia | D001656 | EFO_0004217 | Q44.2 | 2 | — | — | — | — | 2 |
Osteoporosis | D010024 | EFO_0003882 | M81.0 | 1 | — | — | — | — | 1 |
Hand injuries | D006230 | 1 | — | — | — | — | 1 | ||
Osteoarthritis | D010003 | EFO_0002506 | M15-M19 | 1 | — | — | — | — | 1 |
Respiratory insufficiency | D012131 | HP_0002093 | J96.9 | 1 | — | — | — | — | 1 |
Non-small-cell lung carcinoma | D002289 | 1 | — | — | — | — | 1 | ||
Dialysis | D003956 | 1 | — | — | — | — | 1 |
Show 2 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Acute kidney injury | D058186 | HP_0001919 | N17 | — | — | — | — | 2 | 2 |
Colitis | D003092 | EFO_0003872 | K52.9 | — | — | — | — | 2 | 2 |
Bacterial meningitis | D016920 | EFO_1000831 | G00 | — | — | — | — | 1 | 1 |
Acinetobacter infections | D000151 | EFO_1000792 | — | — | — | — | 1 | 1 | |
Cerebral hemorrhage | D002543 | — | — | — | — | 1 | 1 | ||
Subarachnoid hemorrhage | D013345 | EFO_0000713 | I60 | — | — | — | — | 1 | 1 |
Drug monitoring | D016903 | — | — | — | — | 1 | 1 | ||
Mediastinitis | D008480 | J98.51 | — | — | — | — | 1 | 1 | |
Psoriatic arthritis | D015535 | EFO_0003778 | L40.5 | — | — | — | — | 1 | 1 |
Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | — | — | — | — | 1 | 1 |
Show 24 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name | VANCOMYCIN |
INN | vancomycin |
Description | Vancomycin is a complex glycopeptide from Streptomyces orientalis. It inhibits a specific step in the synthesis of the peptidoglycan layer in the Gram-positive bacteria Staphylococcus aureus and Clostridium difficile. It has a role as an antimicrobial agent, an antibacterial drug and a bacterial metabolite. It is functionally related to a vancomycin aglycone. It is a conjugate base of a vancomycin(1+). |
Classification | Small molecule |
Drug class | antibiotics (Streptomyces strain) |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | CN[C@H](CC(C)C)C(=O)N[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]2C(=O)N[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)O)c4cc(O)cc(O)c4-c4cc3ccc4O)[C@H](O)c3ccc(c(Cl)c3)Oc3cc2cc(c3O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O[C@H]2C[C@](C)(N)[C@H](O)[C@H](C)O2)Oc2ccc(cc2Cl)[C@H]1O |
Identifiers
PDB | — |
CAS-ID | 1404-90-6 |
RxCUI | 11124 |
ChEMBL ID | CHEMBL262777 |
ChEBI ID | 28001 |
PubChem CID | 14969 |
DrugBank | DB00512 |
UNII ID | 6Q205EH1VU (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 91,478 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
65,910 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more